Mostrar el registro sencillo

dc.contributor.authorGarcía-Hevia, Lorena
dc.contributor.authorCasafont Parra, Íñigo 
dc.contributor.authorOliveira, Jessica
dc.contributor.authorTerán Villagrá, Nuria 
dc.contributor.authorLópez Fanarraga, Mónica 
dc.contributor.authorGallo, Juan
dc.contributor.authorBañobre-López, Manuel
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2022-01-21T19:36:30Z
dc.date.available2022-01-21T19:36:30Z
dc.date.issued2021
dc.identifier.issn2452-199X
dc.identifier.urihttp://hdl.handle.net/10902/23773
dc.description.abstractNowadays, a number of promising strategies are being developed that aim at combining diagnostic and therapeutic capabilities into clinically effective formulations. Thus, the combination of a modified release provided by an organic encapsulation and the intrinsic physico-chemical properties from an inorganic counterpart opens new perspectives in biomedical applications. Herein, a biocompatible magnetic lipid nanocomposite vehicle was developed through an efficient, green and simple method to simultaneously incorporate magnetic nanoparticles and an anticancer drug (doxorubicin) into a natural nano-matrix. The theranostic performance of the final magnetic formulation was validated in vitro and in vivo, in melanoma tumors. The systemic administration of the proposed magnetic hybrid nanocomposite carrier enhanced anti-tumoral activity through a synergistic combination of magnetic hyperthermia effects and antimitotic therapy, together with MRI reporting capability. The application of an alternating magnetic field was found to play a dual role, (i) acting as an extra layer of control (remote, on-demand) over the chemotherapy release and (ii) inducing a local thermal ablation of tumor cells. This combination of chemotherapy with thermotherapy establishes a synergistic platform for the treatment of solid malignant tumors under lower drug dosing schemes, which may realize the dual goal of reduced systemic toxicity and enhanced anti-tumoral efficacy.es_ES
dc.description.sponsorshipThis work was partially supported by NORTE 2020 (2014–2020 North Portugal Regional Operational Program), and the ERDF (European Regional Development Fund) under Grant NORTE-01-0145-FEDER-000019, by European Union’s Horizon 2020 Research and Innovation Programme under grant agreement No. 686009, by “TAMs-targeted and externally controlled nanotheranostics of triple-negative-breast-cancer (Nanother)" project UTAPEXPL/NTec/0038/2017, by “Local specific treatment of triple-negativebreast-cancer through externally triggered target-less drug carriers (MagtargetON)" project NORTE-01-0145-FEDER-031142, co-funded by FCT and the ERDF through NORTE2020, and by 2014–2020 INTERREG Cooperation Programme Spain–Portugal (POCTEP) through the Project 0624_2IQBIONEURO_6_E. Co-authors also acknowledge support from Raman4clinics COST Action BM1401 and Radiomag COST action TD1402. ML-F also acknowledges the ERDF and the Spanish MINECO under project ref. PI19/00349 (AES 2019). LGH thanks the Instituto de Salud Carlos III for the Sara Borrell Grant (CD19/00035).es_ES
dc.format.extent12 p.es_ES
dc.language.isoenges_ES
dc.publisherKe Ai Publishinges_ES
dc.rights© 2021 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. This is an open access article under the CC BY-NC-ND 4.0 licensees_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceBioactive Materials, 2021, 17(8), 153-164es_ES
dc.subject.otherDrug delivery systemses_ES
dc.subject.otherTheranosises_ES
dc.subject.otherMagnetic hyperthermiaes_ES
dc.subject.otherMagnetic resonance imaginges_ES
dc.subject.otherMelanomaes_ES
dc.titleMagnetic lipid nanovehicles synergize the controlled thermal release of chemotherapeutics with magnetic ablation while enabling non-invasive monitoring by MRI for melanoma theranosticses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://doi.org/10.1016/j.bioactmat.2021.06.009es_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.1016/j.bioactmat.2021.06.009
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

© 2021 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. This is an open access article under the CC BY-NC-ND 4.0 licenseExcepto si se señala otra cosa, la licencia del ítem se describe como © 2021 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. This is an open access article under the CC BY-NC-ND 4.0 license